Rates and reasons for lack of persistence with anti-osteoporotic drugs: analysis of the Campania region database.

Subjects with chronic diseases are more likely to be nonpersistent to pharmacological treatment. Lack of persistence is common among subjects using oral anti-osteoporotic drugs, and leads to increased risk of fragility fracture. The aim of our retrospective study is to analyze the rates and reasons for discontinuation of anti-osteoporotic drugs in the Campania Region. Subjects aged over 40 years were included if they had received at least one prescription for any anti-osteoporotic drugs. Data were obtained from an administrative database of regional data on outpatient drug prescriptions reimbursed by the National Health Service. Patients were followed until the discontinuation of anti-osteoporotic therapy or until the end of the observation period. A total of 30,048 were incident users of anti-osteoporotic drugs: 28,317 (94.2%) females. The mean age of the cohort was 69.0±10.0 years. Weekly bis-phosphonates (51.1%) were the most commonly prescribed drugs. In the overall population, persistence rates were 34.8% after 6 months and 13.4% at one year. A multivariate Cox proportional hazard analysis showed that daily regimen (HR 1.9) treatments remained at higher risk of early discontinuation compared to weekly regimen therapies. Our data showed that the persistence to osteoporosis therapy is significantly worse than reported in literature.

[1]  A. Capaldo,et al.  Osteoporosis drugs in real-world clinical practice: an analysis of persistence , 2013, Aging Clinical and Experimental Research.

[2]  J. V. Boven,et al.  Persistence with osteoporosis medication among newly-treated osteoporotic patients , 2013, Journal of Bone and Mineral Metabolism.

[3]  J. Adams,et al.  Medication adherence and fracture risk among patients on bisphosphonate therapy in a large United States health plan. , 2012, Bone.

[4]  M. Brandi,et al.  The incidence of hip, forearm, humeral, ankle, and vertebral fragility fractures in Italy: results from a 3-year multicenter study , 2010, Arthritis research & therapy.

[5]  I. Imaz,et al.  Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis , 2010, Osteoporosis International.

[6]  S. Silverman,et al.  Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. , 2009, The American journal of medicine.

[7]  S. Rietbrock,et al.  Fracture Outcomes Related to Persistence and Compliance With Oral Bisphosphonates , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[8]  C. Cooper,et al.  European guidance for the diagnosis and management of osteoporosis in postmenopausal women , 2008, Osteoporosis International.

[9]  E. Badamgarav,et al.  Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. , 2007, Mayo Clinic proceedings.

[10]  S. Silverman,et al.  Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. , 2006, Mayo Clinic proceedings.

[11]  S. Giannini,et al.  Determinants of adherence to osteoporosis treatment in clinical practice , 2006, Osteoporosis International.

[12]  S. Emani,et al.  Compliance with pharmacologic therapy for osteoporosis , 2003, Osteoporosis International.

[13]  A. Giusti,et al.  Persistence with calcium and vitamin D in elderly patients after hip fracture , 2008, Journal of Bone and Mineral Metabolism.

[14]  Anuja Roy,et al.  Medication compliance and persistence: terminology and definitions. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[15]  A. Scillitani,et al.  Osteoporosis intervention in ambulatory patients with previous hip fracture: a multicentric, nationwide Italian survey , 2005, Osteoporosis International.